Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Corbus Pharmaceuticals Holding

Current price
23.3 USD -0.5 USD (-2.10%)
Last closed 23.1 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 238 780 080 USD
Yield for 12 month +735.13 %
21.11.2021 - 28.11.2021

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts. Address: 500 River Ridge Drive, Norwood, MA, United States, 02062

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

51 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

Current Quarter

Last Quarter

Key Figures CRBP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -45 093 356 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -51.96 %
PEG Ratio
Return On Equity TTM -224.63 %
Wall Street Target Price 51 USD
Revenue TTM
Book Value 0.07 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100 %
Dividend Yield
Gross Profit TTM -16 136 826 USD
Earnings Share -11.12 USD
Diluted Eps TTM -11.12 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CRBP

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CRBP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:30
Payout Ratio
Last Split Date 14.02.2023
Dividend Date

Stock Valuation CRBP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 8.2564
Price Sales TTM 163.3187
Enterprise Value EBITDA -6.1853
Price Book MRQ 771.0672

Financials CRBP

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CRBP

For 52 weeks

2.11 USD 39.96 USD
50 Day MA 11.96 USD
Shares Short Prior Month 28 046
200 Day MA 8.27 USD
Short Ratio 0.22
Shares Short 464 744
Short Percent 10.54 %

Dynamics of changes in the value of assets




402.79 USD Microsoft Corporation -0.45 (-0.11%)
Detailed analytics

ETF funds



11.59 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) 0 (0%)
Detailed analytics



2031.07 USD Gold +9.2 (+0.46%)
Detailed analytics